INO-3107 (Inovio Pharmaceuticals Inc.) is an injectable plasmid DNA immunotherapy under investigation in combination with electroporation for the treatment of recurrent respiratory papillomatosis in adults.
INO-3107 (Inovio Pharmaceuticals Inc.) is an injectable plasmid DNA immunotherapy under investigation in combination with electroporation for the treatment of recurrent respiratory papillomatosis in adults.
Hayes Report Sale Policy: Hayes will review your request to purchase a report and respond to you. Individuals requesting reports due to a payment denial should contact the involved health insurer for details and information.
Please contact us if you are interested in a Hayes subscription.
Learn more about our Privacy Policy
This site uses cookies. By continuing to use this website, you agree to their use. For details, please review our Privacy Policy